The rate of the primary outcome (composite of cardiovascular death, stroke, or myocardial infarction) was lower with rivaroxaban (2.5 mg twice daily) plus aspirin than with aspirin alone (4.1% vs. 5.4%), but the rate of major bleeding was higher (3.1% vs. 1.9%). The rate of the net-clinical-benefit outcome was lower with rivaroxaban plus aspirin than with aspirin alone (4.7% vs. 5.9%).